MUMBAI, Aug 19 (Reuters) - Shares in Indian drugmaker Glenmark Pharmaceuticals (GLEN.BO) fell as much as 17.4 percent on Wednesday to their lowest in more than a month after the company and partner Forest Laboratories FRX.N said their lung drug failed in mid-stage trial. [ID:nSP458535]
At 0437 GMT, the company’s shares were down 9.4 percent at 237.05 rupees, after falling to as low as 216 rupees.
The 30-share BSE index .BSESN was up 0.2 percent. (Reporting by Pratish Narayanan)